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Abstract 
 The objective of the study was to assess what differences exist between individuals who are 
dependent on opiates and benzodiazepines and compare to those who are dependent on opiates. A 
questionnaire was compiled and administered to patients who had been consecutively admitted to an 
inpatient drug treatment unit. The prevalence of benzodiazepine dependency was 54 per cent [n=34]. 
Patients dependent on benzodiazepines and opiates were significantly older, had been admitted for 
methadone stabilisation and were more likely to have been prescribed a methadone maintenance 
programme prior to admission. They had used heroin longer, benzodiazepines more frequently, at 
larger doses for a longer duration of time and tended to use more drugs in general. They were found to 
be more psychologically vulnerable than those not dependent on benzodiazepines as they were 
significantly more likely to have described a past experience of depression and a past episode of 
deliberate self harm. 
Introduction 
 Benzodiazepine use by polydrug users is an extensive and serious problem. The prevalence of 
use has been recorded at 70 per cent in a study of patients on a methadone maintenance programme, 
whereby the patterns and doses of diazepam used were primarily abusive rather than therapeutic1. An 
estimation of benzodiazepine dependency has been rated as being between 15 per cent and 44 per 
cent2,3,4. Research indicates that benzodiazepine polydrug users are more likely to inject, to share 
injected equipment and have a higher risk of H.I.V. and hepatitis C5,6,7,8,9,10. Darke et al8,9 found that 
benzodiazepines-using methadone maintenance clients had higher levels of depression, anxiety, global 
psychopathology, poorer health and poorer social functioning. Hortog and Tusel11 demonstrated that 
diazepam-using methadone maintenance clients had more drug and psychiatric problems than 
diazepam users alone. 
 The aim of this study was to assess the prevalence and pattern of benzodiazepine dependency 
in a sample of Irish drug users who take opiates and benzodiazepines and who require inpatient 
treatment and to identify differences that exist with other drug users who are not dependent on 
benzodiazepines. 
Method 
 All patients who were consecutively admitted to an inpatient drug treatment unit over a four-
month period were included in the study. The inpatient unit consists of 10 beds and admissions are for 
methadone stabilisation, methadone detoxification and benzodiazepine detoxification programmes. A 
clinical decision on admission was made, separate from the study, to commence a drug user on a 
benzodiazepine detoxification programme when their drug history indicated persistent daily use of 
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benzodiazepines and there was a risk of benzodiazepine withdrawals if they were not commenced on a 
detoxification programme. The benzodiazepine detoxification programme consisted of a reducing 
course of lorazepam, commencing at 1mg 3 times a day, reducing every 3 days with completion of the 
detoxification in 9 days. Extra doses of lorazepam were prescribed if required. 
 A questionnaire was compiled which sought information on demographic details, reasons for 
admission, past psychiatric/psychological problems, pattern of heroin, benzodiazepine and other drug 
use, treatment details pertaining to the admission and subsequent discharge details. The questionnaire 
was administered to patients while an inpatient in the unit. Results from patients who required a 
benzodiazepine detoxification programme were compared to results from the control group of patients 
who did not require a benzodiazepine detoxification programme. All results were subjected to 
appropriate statistical tests of significance including Chi-Square and Fisher’s exact test. Statistical 
significance was set at p<0.05. Predictor variables were identified through Logistic Regression 
analysis. 
Results 
 The total sample consisted of 63 admissions, 34 [54 per cent] required a benzodiazepine 
detoxification programme and the remaining 29 [46 per cent] constituted the control group. There 
were no significant gender differences between the 2 groups, but more females [61.8 per cent n=21] 
required a benzodiazepine detoxification programme. The benzodiazepine detoxification group were 
significantly older than the control group, with a mean age of 26.5 yr compared to 22 yr, p=0.004. 
There were no significant differences between the groups regarding marital, employment and 
educational status or in the number of first admission and repeated admission, although a greater 
proportion of patients in the benzodiazepine detoxification group had more repeated admission 
compared to the control group (Table I). 
TABLE 1 
Demographic Characteristics of the Sample 
 Control Group Benzodiazepine Detoxification 
Group 
Sex 
 
Martial Status 
 
 
 
Employment Status 
Educational Status 
 
 
School Exams 
First admission 
M: 58.6% [n=17] 
F: 41.4% [n=12] 
Single: 69% [n=20] 
Married/Co-habitating: 27.6% [n=8] 
Separated: 3.45% [n=11] 
Widowed: 0% 
Unemployed: 96.55% [n=28] 
Primary School: 13.8% [n=4] 
Secondary School: 86.2% [n=25] 
Higher Education: 0% 
34.5% [n=10] 
72.4% [n=21] 
M:3802% [n=13] 
F: 61.8% [n=21] 
Single: 67.65% [n=23] 
Married/Co-habitating: 20.6% [n=7] 
Separated: 5.9% [n=2] 
Widows: 5.9% [n=2] 
Unemployed: 94.1% [n=32] 
Primary School: 26.5% [n=9] 
Secondary School: 70.6% [n=24] 
Higher Education: 2.9% [n=1] 
20.6% [n=7] 
52.9% [n=18] 
 More patients who had a benzodiazepine detoxification programme described having a past 
psychiatric history or previous psychological problems, 32.35 per cent [n=11] compared to 13.8 per 
cent [n=4] in the control group, p=0.14. Of these, significantly more in the benzodiazepine 
detoxification group [n=10] described suffering subjective feelings of depression in the past, in 
contrast to 2 in the control group, p=0.045. Individuals who had received a benzodiazepine 
detoxification programme were significantly more likely to have had episodes of deliberate self harm, 
29.4 per cent [n=10] compared to 6.9 per cent [n=10] in the control group, p=0.045. These episodes 
were specifically carried out by patients who had described previous episodes of depression, p=0.001 
(Table II). Few patients from either group described ever having problematic alcohol use. 
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 Significantly more patients who had received a benzodiazepine detoxification programme had 
been prescribed methadone as part of a methadone maintenance programme prior to admission, 67.65 
per cent [n=23] compared to 37.9 per cent [n=11] in the control group, p=0.024 and they tended to 
received a higher average daily methadone dose of 45mg, in contrast to 34.4 mg for the control group, 
p=0.052. Significantly more in the benzodiazepine detoxification group had been admitted to the 
inpatient unit for stabilisation of methadone, 58.8 per cent [n=20] vs 13.8 per cent [n=4] in the control 
group. whereas significantly more in the control group had been admitted for a methadone 
detoxification programme, p=0.0002. 
 The infection status for both groups was compared. Three from the benzodiazepine 
detoxification group had H.I.V. status positively identified, 1 from the control group and 3 from the 
benzodiazepine group had hepatitis B. Although more in the benzodiazepine detoxification group had 
hepatitis C, 70.6 per cent [n=24] compared to 48.3 per cent [n=14], this was not found to be 
statistically significant. The prevalence of hepatitis C in the sample was 60.3 per cent. 
TABLE II 
Past psychiatric history/psychological difficulties 
 
 
 
Per cent of each group 
Control 
group 
n=4 [6.3%] 
      [13.8%] 
Benzodiazepine 
detoxification group 
n=11 [17.5%] 
          [32.35%] 
Percent of the total 
sample 
n=15 [23.8%] 
 
Depression 2 [6.9%] *10 [29.4%] 12 [19%] 
Schizophrenia 0% 1 [2.9] 1[1.6%] 
Learning difficulties 2 [6.9%] 0% 2 [3.2%] 
Alcohol use 0% 1 [2.9%] 1 [1.6%] 
Deliberate self harm 2 [6.9%] *10 [29.4%] 12 [19%] 
*p=<0.05 
Pattern of heroin use 
 The mean age of the control group to commence taking any drug was 1 5.8 yr, and 15.5 yr for 
the benzodiazepine detoxification group. Patients in the benzodiazepine detoxification group were 
using heroin significantly longer than the control group i.e. 6.8 yr compared to 3.2 yr, p=0.005. The 
most common frequency of use was daily with 100 per cent [n=22] of the control group and 85.2% 
[n=23] of the benzodiazepine detoxification group taking heroin daily. There was no significant 
difference in the average number of grams of heroin taken by each group, 1 gram for the control group 
and 1.2 grams for the benzodiazepine detoxification group. The route of administration of heroin was 
comparable in both groups although more in the benzodiazepine detoxification group injected 
(Figure 1). 
 
Fig. 1 – Routes of Administration of Heroin 
4 
Other substance use 
 A greater percentage in the benzodiazepine detoxification group used cannabis, cocaine, 
amphetamines and particularly antidepressants [p=0.052] and to have taken these drugs over a longer 
period of time (Table III). The frequency of use of all these drugs was comparable between the 2 
groups except for antidepressants which were taken significantly more frequently by the 
benzodiazepine detoxification group, p=0.012. 
Benzodiazepine use 
 The average age for commencing benzodiazepine use was similar in both groups, 15.3 yr and 
16.8 yr for the control group and benzodiazepine detoxification group respectively. As one would 
expect because of the nature of the study, patients who had a benzodiazepine detoxification 
programme significantly used more benzodiazepines than the control group, p=0.007. However, a 
large amount of patients in the control group, 79.3 per cent [n=23], had taken benzodiazepines at some 
stage, but their use was not daily and was at lower doses than for the benzodiazepine detoxification 
group. 
 The most popular benzodiazepines used by both groups were flunitrazepam, diazepam and 
flurazepam (Table IV). Flunitrazepam, diazepam and flurazepam were used at higher doses, more 
frequently and generally for a longer duration of time by patients in the benzodiazepine detoxification 
group. Frequency was on a daily or 2 to 6 times a week basis as opposed to patients in the control 
group who tended not to have used these benzodiazepines within the last month. The average daily 
doses of the 3 most popular benzodiazepines used were 115.5mg for diazepam, 8.5mg for 
flunitrazepam and 233.6mg for flurazepam (Table IV). 
TABLE III 
A Comparison to Other Drug Use 
 Cannabis Cocaine Amphetamines Ecstasy Antidepressants 
Control group 
Benzodiazepine 
detoxification group 
Duration of use 
Control group 
Benzodiazepine 
detoxification group 
Frequency of daily 
use 
Control group 
Benzodiazepine 
detoxification group 
n=17 [58.6%] 
n=25 [73.5%] 
 
 
8.6 yrs 
11.3 yrs 
 
 
 
n=8 [47.1%] 
n=9 [36%] 
 
n=4 [13.8%] 
*n=12 [35.3%] 
 
 
2.8 yrs 
4 yrs 
 
 
 
n=1 
n=2 
 
n=3 [10.3%] 
n=6 [17.7%] 
 
 
4.3 yrs 
7.4 yrs 
 
 
 
0 
0 
 
n=9 [31%] 
n=9 [26.5%] 
 
 
2 yrs 
** 4.4 yrs 
 
 
 
 
 
 
n=2 [6.9%] 
***n=9 [26.5%] 
 
 
1.5 yrs 
2.7 yrs 
 
 
 
0 
****n=5 
 
*p=0.08 **p=0.07 ***p=0.0052 ****p=0.012 
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TABLE IV 
The Most Popular Benzodiazepine Used 
  Control 
group 
Benzodiazepine 
detoxification 
group 
Rohypnol 
 
 
 
 
Valium 
 
 
 
Dalmane 
 
*%/n 
*Daily use [%/n] 
*Duration [yrs] 
*Average dose [mg] 
*%/n 
*Daily use [%/n] 
*Duration [yrs] 
*Average dose [mg] 
%/n 
*Daily use [%/n] 
*Duration [yrs] 
*Average dose [mg] 
44.8% [n=13] 
7.7% [n=1] 
2.8 
1.25 
65.5% [n=19] 
5.3% [n=1] 
3.9 
8.9 
51.7%[n=15] 
13.3% [n=2] 
3.3 
38.7 
91.2% [n=31] 
48.4% [n=15] 
4.4 
8.5 
88.2% [n=30] 
60% [n=18] 
7.3 
115.5 
70.6% [n=24] 
62.5% [n=15] 
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233.6 
*p < 0.05 
 Other benzodiazepines that were used by the benzodiazepine detoxification group included, 
alprazolam [n=3], chlormethiazole [n=1] and zopiclone [n=1]. Zopiclone had also been used by a 
patient in the control group as too was temazepam [n=2], lorazepam [n=1] and chlordiazepoxide 
[n=1]. 
 There were no significant differences in the mode that benzodiazepines were used between 
the 2 groups, with 16 [69.6 per cent] in the control group and 22 [64 per cent] in the benzodiazepine 
detoxification group taking benzodiazepines orally. 
Treatment details 
 As expected there were significantly more patients in the benzodiazepine detoxification group 
who had benzodiazepines in their urine, 97.1 per cent [n=33] compared to 24.1 per cent [n=7] in the 
control group, p=0.00. Of the 7 in the control group whose urines were positive for benzodiazepines 
only 1 had used benzodiazepines daily. They had similar preferences for specific benzodiazepines as 
the benzodiazepine detoxification group but their average dose of use was much lower, with an 
average dose for diazepam of 8.9mg, 1.25mg for flunitrazepam and 38.7mg for flurazepam when 
taken (Table IV). 
 Of those in the benzodiazepine detoxification group, 82.3 per cent [n=28] subjectively 
experienced benzodiazepine withdrawals. Withdrawals were most commonly reported as occurring 
within the first 48 hr of admission, 64.3 per cent [n=18], 21.4 per cent [n=6] experienced withdrawals 
between 48 and 72 hr and 10.7 per cent [n=3) experienced them after 48 hr. Lorazepam was 
prescribed in 31 cases [91.2 per cent] or combined with diazepam in another 2 cases, accounting for 
33 treatment episodes. The average maximum dose of lorazepam used was 2.9mg, range between 1 
and 6mg and 15mg for diazepam. The final case was treated with chlordiazepoxide because of an 
associated history of alcohol dependency, at a maximum dose of 60mg. The mean duration of a 
benzodiazepine detoxification programme was 8.4 days and the programme was completed in 30 of 
the 34 treatment episodes. The remainder had taken their own discharge against medical advice prior 
to completion of the programme. 
 Discharge status indicated that significantly more form the benzodiazepine detoxification 
group were discharged back to the National Drug Treatment Unit [55.9 per cent, n=19, p=0.001] and 
more from the control group were discharged to the general practitioner [37.9 per cent, n=11] vs 0 per 
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cent in the benzodiazepine detoxification group] or to the rehabilitative services [34.5 per cent, n=10] 
(Figure 2). 
 
Discussion 
 In view of the small sample size, the results in this study may not be representative of all Irish 
drug users. However the prevalence of benzodiazepine dependency was found to be 54 per cent. This 
is higher than the quoted prevalence rate of 15-44 per cent in other studies2,3,4.  
 Predictor variables identified for those who require a benzodiazepine detoxification 
programme included, age, reasons for admission and discharge status. This group was significantly 
older, the majority had been admitted for a methadone stabilisation programme and were primarily 
discharged back to the referring drug treatment centre for continued treatment and supervision of 
urines. Although more women required a benzodiazepine detoxification programme, this was not 
found to be significant and would not be representative of the general drug using population. 
 Both groups stated taking drugs and benzodiazepines at similar ages, however those 
dependent on benzodiazepines had used heroin and other drugs for a longer period of time with 
benzodiazepine being taken daily and at higher doses. This group also tended to take more drugs in 
general, particularly cocaine and antidepressants, with antidepressants being taken significantly more 
frequently. The more frequent use of antidepressants may have been a means of treating the 
withdrawals from cocaine. 
 Despite there being 2 groups compared in the study, it is evident that the control group were 
not adverse to taking benzodiazepines, with only 20.7 per cent [n=6] having never taken 
benzodiazepines. Patients who had used benzodiazepines in the control group did so less frequently 
and at lower doses than those in the benzodiazepine detoxification group. This difference may only be 
because of the shorter duration of drug use by the control group and benzodiazepine dependency may 
still develop in this group over time in conjunction with continued opiate and other drug use. 
 In other studies the popularity of particular benzodiazepines that are used has varied. 
Williams et al. found that diazepam and temazepam were most popular12, Gantry et al. identified 
nitrazepam, chlordiazepoxide and temazepam13 and Iguchi et al. rated diazepam, lorazepam and 
alprazolam as the most preferred benzodiazepines used14. Great concerns have also been expressed 
towards the injection of temazepam5,15,16. In this study the use of temazepam is low, with only 2 in the 
control group having used it and no person in the benzodiazepine detoxification group using it. The 
most popular benzodiazepines used in this study were flunitrazepam, diazepam and fluazepam. The 
average dose of diazepam used is higher than in other studies1,12,17. Zopiclone is emerging as a new 
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drug of use with 2 people in the sample using it despite studies indicating that the drug users have “no 
liking” for the drug and therefore it has less potential for misuse18. This emerging trend of zopiclone 
being a drug of misuse has previously been documented19. 
 A subjective awareness of benzodiazepine withdrawal symptoms in the majority of cases 
(64.3 per cent) was within the first 48 h, a similar rate as in the study by Williams et al.12. The early 
onset of symptoms was most likely as a result of a reduction in the amount of benzodiazepines that 
had been taken daily. The average duration of benzodiazepine detoxification was 8.4 days which, 
although it is shorter than in other studies12, treatment and supervision of urines was continued in the 
National Drug Treatment Centre on discharge, in 55.9 per cent [n=19] of cases. Significantly more in 
the control group were discharged to G.P.s or to the rehabilitative services reflecting a greater 
potential to complete medical treatment for drug dependency, a movement towards exploring the 
psychological aspects of drug dependency and a drug-free life. This is not the picture with 
benzodiazepine dependency as these patients had previously been on methadone maintenance 
programmes, had been admitted for methadone stabilisation and were being discharged back to their 
treatment centre to continue a methadone maintenance programme and with that the opportunity for 
continued stabilisation of drug-use and thus life style. 
 A result of concern in this study, is that benzodiazepine dependency was associated with 
greater psychological vulnerability. This group experienced a higher rate of subjective feelings of 
depression and episodes of deliberate self harm than the control group, confirming previous 
studies8,9,11. This may also explain why a greater percentage use antidepressants and use them more 
frequently. However despite a higher subjective reporting of psychological distress, none of the clients 
were regularly attending or obtaining treatment from a psychiatric service. 
 Although there were 2 groups of drug users compared in this study, the results indicate that 
these groups are not distinct, but represent differing parts of the spectrum of severity of drug-use. The 
main differentiating factor between the 2 groups was the longer duration and greater severity 
(frequency and amount) of drug use by clients who were also dependent on benzodiazepines and with 
that came difference of treatment programmes. The longer the duration of drug use, the greater the risk 
of an inevitable progressive deterioration in drug dependency and deterioration of psychological 
health. 
 It is therefore paramount that doctors ensure a strict control in prescribing benzodiazepines. 
The risk of benzodiazepines dependency in polydrug users can be reduced by decreasing the supply of 
availability of benzodiazepine through educating doctors on the dangers of long-term and 
indiscriminate prescribing of benzodiazepines. It is important that doctors do not legitimate 
benzodiazepine use by continuing to prescribe them to drug users. Drug treatment programmes need 
to focus on and re-evaluate the present treatments for benzodiazepine dependency as continued 
benzodiazepine use leads to destabilisation of methadone maintenance programmes. Resources need 
to be concentrated towards the younger drug user to promote drug treatment programmes that focus on 
and support the young drug-user in achieving a drug-free life. 
 Benzodiazepine dependency in this study has been associated with greater drug use and 
greater psychological morbidity. Reducing its prevalence will improve psychological and medical 
stability for drug users in treatment programmes and protect younger drug users from developing 
benzodiazepine dependency. 
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